Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer:: Specific role of class I histone deacetylases in vitro and in vivo

被引:318
作者
Weichert, Wilko [1 ]
Roeske, Annika [1 ]
Niesporek, Silvia [1 ]
Noske, Aurelia [1 ]
Buckendahl, Ann-Christin [1 ]
Dietel, Manfred [1 ]
Gekeler, Volker [2 ]
Boehm, Markus [2 ]
Beckers, Thomas [2 ]
Denkert, Carsten [1 ]
机构
[1] Charite Univ Med Berlin, Inst Pathol, D-10117 Berlin, Germany
[2] Altana Pharma AG, Therapeut Area Oncol, Constance, Germany
关键词
D O I
10.1158/1078-0432.CCR-07-0990
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Recently, several studies reported a strong functional link between histone deacetylases (HDAC) and the development of tumors of the large intestine. However, despite the importance of these molecules, comparably little is known on expression patterns and functions of specific HDAC isoforms in colorectal cancer. Experimental Design: We characterized class I HDAC isoform expression patterns in a cohort of 140 colorectal carcinomas by immunohistochemistry. In addition, effects of HDAC inhibition by valproic acid and suberoylanilide hydroxamic acid, and specific HDAC isoform knockdown by short interfering RNA, were investigated in a cell culture model. Results: We found class I HDACs highly expressed in a subset of colorectal carcinomas with positivity for HDAC1 in 36.4%, HDAC2 in 57.9%, and HDAC3 in 72.9% of cases. Expression was significantly enhanced in strongly proliferating (P = 0.002), dedifferentiated (P = 0.022) tumors. High HDAC expression levels implicated significantly reduced patient survival (P = 0.001), with HDAC2 expression being an independent survival prognosticator (hazard ratio, 2.6; P = 0.03). Short interfering RNA-based inhibition of HDAC1 and HDAC2 but not HDAC3 suppressed growth of colon cancer cells in vitro, although to a lesser extent than chemical HDAC inhibitors did. Conclusions: The strong prognostic impact of HDAC isoforms in colorectal cancer, the interactions of HDACs with tumor cell proliferation and differentiation in vivo, and our finding that HDACs are differentially expressed in colorectal tumors suggest that the evaluation of HDAC expression in clinical trials for HDAC inhibitors might help to identify a patient subgroup who will exceptionally profit from such a treatment.
引用
收藏
页码:1669 / 1677
页数:9
相关论文
共 40 条
[1]  
Aggarwal S, 2005, ONCOLOGY-NY, V19, P589
[2]   Selective growth inhibition of tumor cells by a novel histone deacetylase inhibitor, NVP-LAQ824 [J].
Atadja, P ;
Gao, L ;
Kwon, P ;
Trogani, N ;
Walker, H ;
Hsu, M ;
Yeleswarapu, L ;
Chandramouli, N ;
Perez, L ;
Versace, R ;
Wu, A ;
Sambucetti, L ;
Lassota, P ;
Cohen, D ;
Bair, K ;
Wood, A ;
Remiszewski, S .
CANCER RESEARCH, 2004, 64 (02) :689-695
[3]   Microsatellite instability and colorectal cancer prognosis [J].
Benatti, P ;
Gafà, R ;
Barana, D ;
Marino, M ;
Scarselli, A ;
Pedroni, M ;
Maestri, I ;
Guerzoni, L ;
Roncucci, L ;
Menigatti, M ;
Roncari, B ;
Maffei, S ;
Rossi, G ;
Ponti, G ;
Santini, A ;
Losi, L ;
Di Gregorio, C ;
Oliani, C ;
de Leon, MP ;
Lanza, G .
CLINICAL CANCER RESEARCH, 2005, 11 (23) :8332-8340
[4]   Induction and superinduction of growth arrest and DNA damage gene 45 (GADD45) α and β messenger RNAs by histone deacetylase inhibitors trichostatin A (TSA) and butyrate in SW620 human colon carcinoma cells [J].
Chen, ZX ;
Clark, S ;
Birkeland, M ;
Sung, CM ;
Lago, A ;
Liu, RG ;
Kirkpatrick, R ;
Johanson, K ;
Winkler, JD ;
Hu, ED .
CANCER LETTERS, 2002, 188 (1-2) :127-140
[5]   Modulation of radiation response by histone deacetylase inhibition [J].
Chinnaiyan, P ;
Vallabhaneni, G ;
Armstrong, E ;
Huang, SM ;
Harari, PM .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2005, 62 (01) :223-229
[6]   Differential display cloning of a novel human histone deacetylase (HDAC3) cDNA from PHA-activated immune cells [J].
Dangond, F ;
Hafler, DA ;
Tong, JK ;
Randall, J ;
Kojima, R ;
Utku, N ;
Gullans, SR .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1998, 242 (03) :648-652
[7]   Clinical development of histone deacetylase inhibitors as anticancer agents [J].
Drummond, DC ;
Noble, CO ;
Kirpotin, DB ;
Guo, ZX ;
Scott, GK ;
Benz, CC .
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 2005, 45 :495-528
[8]   Mutations truncating the EP300 acetylase in human cancers [J].
Gayther, SA ;
Batley, SJ ;
Linger, L ;
Bannister, A ;
Thorpe, K ;
Chin, SF ;
Daigo, Y ;
Russell, P ;
Wilson, A ;
Sowter, HM ;
Delhanty, JDA ;
Ponder, BAJ ;
Kouzarides, T ;
Caldas, C .
NATURE GENETICS, 2000, 24 (03) :300-303
[9]   Role of Class I and Class II histone deacetylases in carcinoma cells using siRNA [J].
Glaser, KB ;
Li, JL ;
Staver, MJ ;
Wei, RQ ;
Albert, DH ;
Davidsen, SK .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2003, 310 (02) :529-536
[10]   Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells [J].
Göttlicher, M ;
Minucci, S ;
Zhu, P ;
Krämer, OH ;
Schimpf, A ;
Giavara, S ;
Sleeman, JP ;
Lo Coco, F ;
Nervi, C ;
Pelicci, PG ;
Heinzel, T .
EMBO JOURNAL, 2001, 20 (24) :6969-6978